1. Wegovy (semaglutide 2.4mg), closest pharmaceutical match
Same active molecule as Ozempic, just dosed higher. Switching is straightforward at equivalent doses (Ozempic 0.5mg → Wegovy 0.5mg). The main barrier is cost: Wegovy is not PBS-subsidised, so T2D patients moving from PBS Ozempic ($31.60/month) to private Wegovy ($420-$530/month) face a 14x cost jump.
For weight-loss patients already paying privately, the cost increase is marginal and Wegovy is often the better choice anyway (higher doses, on-label for weight management). See Ozempic vs Wegovy.
2. Mounjaro (tirzepatide), different mechanism
Dual GIP/GLP-1 receptor agonist from Eli Lilly. Different active molecule and different supply chain to Ozempic. Trial-reported weight-change ranges differ between the SURMOUNT (tirzepatide) and STEP (semaglutide) programmes — see the TGA Product Information. Not currently PBS-listed; private retail pricing varies by pharmacy.
Switching between prescription medicines is a clinical decision for your prescriber. See Ozempic vs Mounjaro for general comparison.
3. Trulicity (dulaglutide), PBS alternative for T2D
Eli Lilly's once-weekly GLP-1 agonist. TGA-approved and PBS-subsidised for type 2 diabetes under specific Authority criteria. Often the best switch for PBS Ozempic patients during shortages because PBS pricing is preserved. Auto-injector device is well-designed.
Discuss with your prescriber. Eligibility under PBS may require different criteria than Ozempic Authority Streamlined.
4. Saxenda (liraglutide), daily injection alternative
Older GLP-1 agonist, daily injection rather than weekly. Less effective for weight loss than Ozempic at maximum dose, but supply is generally stable. Private cost only ($340-$420/month).
Mostly chosen by patients who prefer daily smaller injections to weekly larger ones, or those who tolerated semaglutide poorly. Saxenda cost guide.
5. Rybelsus (oral semaglutide), pill form
Same molecule as Ozempic but in tablet form. Taken daily on empty stomach. TGA-approved for T2D, with PBS access for some indications. Not typically used for weight loss because available doses are lower-equivalent than injectable Ozempic.
Useful if injectable supply is short and you can tolerate the strict pre-dose fasting requirements (no food/drink 30 minutes before or after).
6. Metformin, PBS-subsidised, first-line for T2D and PCOS
Decades-old, cheap, PBS-subsidised diabetes medication. Produces modest weight loss (2-4kg typical). Often used as a bridge during Ozempic shortages for T2D patients, or as adjunct to other weight loss approaches.
For PCOS patients specifically, metformin is first-line PBS-subsidised treatment and a sensible alternative if Ozempic access is the issue. Less effective for weight loss than GLP-1s but materially better than nothing.
7. Bariatric surgery, for BMI 35+ patients
Sleeve gastrectomy or gastric bypass produces greater long-term weight loss than GLP-1 medications (typically 25-30% body weight) with durability that does not require ongoing medication. Worth considering for patients facing years of expensive private GLP-1 therapy.
Cost: $20,000-$25,000 privately. Public waitlists run 6-12+ months in most states. Some private health insurance covers a significant portion if you have hospital cover with appropriate tier and bariatric coverage.
See our bariatric surgery cost guide.
8. Orlistat (Xenical/Alli), over-the-counter option
The only over-the-counter weight loss medication available in Australia. Works by reducing fat absorption in the gut. Modest efficacy (5-10% weight loss over 12 months) and challenging side effect profile (oily stools, faecal urgency, anal leakage when high-fat meals are consumed).
Not a GLP-1 substitute for efficacy, but the only no-prescription option. Compliance is the main issue.
9. Phentermine (Duromine), appetite suppressant
Stimulant appetite suppressant, available on private prescription only. Produces meaningful short-term weight loss but with cardiovascular risks (raised heart rate, blood pressure) and dependence potential. Not suitable for patients with cardiovascular disease, anxiety disorders, or substance use history.
Generally used short-term (12-16 weeks) rather than long-term. Worth discussing with your prescriber if you need a bridge during GLP-1 unavailability and have no cardiovascular contraindications.
10. Structured behavioural programme, non-pharmaceutical
If GLP-1 access is genuinely unavailable for an extended period, a structured behavioural weight management programme produces meaningful results for many patients. Includes registered dietitian input, exercise programming, and behavioural change support.
Medicare-rebated dietitian visits are available with a GP referral under Chronic Disease Management Plan. Less dramatic than GLP-1 medications but durable and side-effect-free. Often used as an adjunct rather than a sole alternative.
What to AVOID as an "alternative"
- Compounded semaglutide. Not TGA-assessed. AHPRA has issued cautions. Not a legitimate substitute.
- Personal importation from overseas. Restricted, not recommended, no cold-chain assurance.
- "Pharmacy" sales via social media. Counterfeit Ozempic has been seized by TGA. Stick to registered Australian pharmacies.
- HCG injections, "weight loss tea", herbal supplements. No evidence base, often regulatory issues.
- Extreme caloric restriction. Without medical supervision can cause muscle loss, gallstones, and rebound weight gain.